AMCP 2021 Symposium Highlights—Evaluating JAK Inhibition in Inflammatory Skin Conditions: Outcomes and Benefit Design Implications

AMCP 2021 Symposium Highlights—Evaluating JAK Inhibition in Inflammatory Skin Conditions: Outcomes and Benefit Design Implications

Med-IQ Select
Continue to Course
Expiring Soon
Online Course | Specialties: Dermatology
Released: 7/6/2021
Expires: 7/5/2022
Max Credits: 1.5
Continue to Course Read Abstract

Leslie A. Castelo-Soccio, MD, PhD
Assistant Professor, Section of Dermatology
Department of Pediatrics
The Children's Hospital of Philadelphia
University of Pennsylvania, Perelman School of Medicine
Philadelphia, PA

Jeffrey Dunn, PharmD, MBA
Head of Clinical Pharmacy
Berkshire Hathaway (The Legacy Haven HealthCare Venture)
Draper, UT

Jonathan I. Silverberg, MD, PhD, MPH
Associate Professor of Dermatology
Director of Clinical Research, Department of Dermatology
George Washington University School of Medicine and Health Sciences
Washington, DC

Activity Planners
Susan Kuhn, MHSc
Manager, Educational Strategy and Content
Baltimore, MD

Samantha Gordon, MS
Accreditation Manager
Baltimore, MD

Amy Sison
Director of CME
Baltimore, MD

Learning Objectives
Upon completion, participants should be able to:

  • Identify the clinical, psychosocial, and socioeconomic effects of AD, AA, and associated comorbidities
  • Explain the role of the JAK-STAT pathway in the pathophysiology of AD and AA and its potential as a therapeutic target in these conditions
  • Evaluate the safety, efficacy, and pharmacology of new and emerging JAK inhibitors for the treatment of AD and AA
  • Consider the clinical and cost implications of new and emerging JAK inhibitors for the treatment of AD and AA in formulary placement and benefits design

Target Audience
This activity is intended for managed care pharmacists, pharmacy benefits managers, pharmacy directors, community pharmacists, specialty pharmacists, medical directors, health economics professionals, and other formulary and plan decision makers within managed healthcare organizations.

Statement of Need
Historically considered to be superficial conditions, AD and AA are now recognized to have significant personal, clinical, and economic effects, with more severe disease associated with increased burden. In addition, the treatment landscape for AD and AA is rapidly changing because of a greater understanding of the systemic nature of immunologic skin conditions and the role of the JAK-STAT pathway in inflammation. These research advances have led to the emergence of JAK inhibitors for the treatment of AD and AA and other immunologic dermatoses. With several JAK inhibitors in late-stage development, managed care pharmacists and decision makers require a greater understanding of the burden of AD and AA, the pathophysiologic underpinnings that form the basis for new targeted treatments (ie, JAK inhibitors), and methods for integrating these treatments into formulary discussions and benefit design.

Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACPEMed-IQ is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) of credit for pharmacists. ACPE # 0476-0000-21-005-H01-P. This application-based activity is designed for all pharmacists.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Medium/Method of Participation
This is a 1.5-credit CE activity. To receive credit, read the introductory CE material, complete all of the modules, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly. Pharmacists will have credits uploaded directly to NABP.

Initial Release Date: July 6, 2021
Expiration Date: July 5, 2022
Estimated Time to Complete This Activity: 1 hour and 30 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 24 months that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Off-label/unapproved drug uses or products are mentioned within this activity.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.

Leslie A. Castelo-Soccio, MD, PhD
Consulting fees/advisory boards: Pfizer, Inc.
Contracted research: Pfizer, Inc.

Jeffrey Dunn, PharmD, MBA, has indicated no real or apparent conflicts.

Jonathan I. Silverberg, MD, PhD, MPH
Consulting fees/advisory boards: AbbVie Inc., AFYX Therapeutics, Arena Pharmaceuticals Inc., Asana BioSciences, BiomX, Bluefin Pharmaceuticals, Bodewell, Boehringer Ingelheim Pharmaceuticals, Inc., Celgene Corporation, Dermavant, Dermira, Eli Lilly and Company, Galderma Laboratories, L.P., GlaxoSmithKline, Incyte Corporation, Kiniksa Pharmaceuticals, Ltd., LEO Pharma, Inc., Luna Pharma, Menlo Therapeutics, Novartis Pharmaceuticals Corporation, Pfizer, Inc., RAPT Therapeutics, Regeneron Pharmaceuticals, Inc., Sanofi-aventis U.S. Inc.
Fees received for promotional/non-CME activities: Eli Lilly and Company, Pfizer, Inc. Regeneron Pharmaceuticals, Inc., Sanofi-aventis U.S. Inc.
Contracted research: Galderma Laboratories, L.P., Pfizer, Inc.

The peer reviewers and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email

System Requirements



  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit:

This activity is available free of charge to participants.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Pfizer, Inc.



Welcome to this Med-IQ Select on evaluating inflammatory skin conditions, specifically atopic dermatitis (AD) and alopecia areata (AA), and the implications for clinical, psychosocial, and economic outcomes and benefit design. Med-IQ Select is a unique online educational offering that allows you to pick and choose the content you would like to view—in any order and at your convenience. Key clinical takeaways from this activity include:

  • Moderate-to-severe AD is associated with serious clinical, psychological, and economic consequences, including an estimated annual economic burden of more than $5.3 billion
  • AA affects 6.8 million Americans, of whom 5% progress to having more severe forms such as alopecia totalis and alopecia universalis
  • AD and AA are associated with multiple psychological and autoimmune comorbidities including atopy
  • Current treatments for moderate-to-severe AD and AA are limited by variable response, side effects, adherence and convenience issues, and patient dissatisfaction
  • Advances in understanding the systemic nature of AD and AA have identified the JAK-STAT pathway as a key target for therapeutic development
  • JAK-mediated cytokine signaling drives:
    • IL-4, IL-13, IL-31, and IL-22 (lesional skin, skin barrier integrity, and epidermal thickening in AD)
    • IL-31 and TSLP (pruritogenic cytokines)
    • IFNγ-driven inflammation and IL-15 in AA (amplifies feedback loop)
  • The treatment landscape for moderate-to-severe AD and AA is evolving rapidly with the introduction of JAK inhibitors where, respectively, few or no targeted treatments exist
  • JAK inhibitors in late-phase development for AD include oral formulations (abrocitinib, baricitinib, and upadacitinib) and topicals (brepocitinib, delgocitinib, ruxolitinib)
  • JAK inhibitors in development for AA include oral baricitinib, ritlecitinib, ruxolitinib, and deuterated ruxolitinib and ruxolitinib cream
  • Benefit design for inflammatory dermatoses (ie, AD, AA) must evolve to maintain a balance between access, appropriate use, patient care, and cost management

View reference list.

Click "Continue" to proceed through this activity and/or receive credit. To receive credit and a certificate, you must complete all of the modules in this activity.

By clicking "Continue," you confirm that you have reviewed the CME information.


Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.